Dibbendhu Khanra1, Abdul Hamid1, Saurabh Deshpande2, Anindya Mukherjee3, Sanjiv Petkar2, Mohammad Saeed4, Indranill Basu-Ray5. 1. Heart and Lung Centre, New Cross Hospital, Royal Wolverhampton NHS Trust; Wolverhampton-United Kingdom. 2. Department of Cardiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research; Bangalore-India. 3. Department of Cardiology, Nilratan Sircar Medical College; Kolkata-India. 4. Department of Cardiology, Baylor College of Medicine; Texas-USA. 5. Memphis VA Medical Center; Tennessee-USA; School of Public Health, The University of Memphis; Tennessee-USA; Department of Cardiology, All India Institute of Medical Sciences (AIIMS); Rishikesh-India.
Abstract
OBJECTIVE: High power short duration (HPSD) ablation strategy is proposed to be more effective than low power long duration (LPLD) for radiofrequency ablation of atrial fibrillation. Although small trials abound, data from a large cohort are lacking. This meta-analysis compares all the existing studies comparing these two approaches to evaluate perceived advantages of one over the other. METHODS: A systematic search of PubMed, EMBASE, and Cochrane databases identified studies comparing HPSD to LPLD ablation. All the analyses used the random-effects model. RESULTS: Ablation settings varied widely across 20 studies comprising 2,136 patients who underwent HPSD and 1,753 patients who underwent LPLD. The pooled incidence of atrial arrhythmia recurrence after HPSD ablation was 20% [95% confidence interval (CI): 0.16-0.25; I2=88%]. Atrial arrhythmia recurrences were significantly less frequent with HPSD ablation (incidence risk ratio=0.66; 95% CI: 0.49-0.88; I2=72%; p=0.004). Procedural, fluoroscopy, and ablation times were significantly shorter with HPSD ablation. First-pass pulmonary vein isolations (PVIs) were significantly more [odds ratio (OR)=2.94; 95% CI: 1.50-5.77; I2=89%; p=0.002), and acute pulmonary vein reconnections (PVRs) were significantly lesser (OR=0.41; 95% CI: 0.28-0.62; I2=62%; p<0.001) in the HPSD group. Although radiofrequency energy was significantly higher, esophageal thermal injuries (ETI) were lower with HPSD ablation. Acute complications, including steam-pops, were rare and statistically similar in both the groups. CONCLUSION: HPSD ablation enables faster first-pass PVI with fewer PVRs, similar ETI rates, rare collateral damage, and lower recurrence of atrial arrhythmia in the long term than LPLD. Randomized controlled studies with a larger cohort are indicated both to confirm the benefit of HPSD ablation and standardize the ablation protocol.
OBJECTIVE: High power short duration (HPSD) ablation strategy is proposed to be more effective than low power long duration (LPLD) for radiofrequency ablation of atrial fibrillation. Although small trials abound, data from a large cohort are lacking. This meta-analysis compares all the existing studies comparing these two approaches to evaluate perceived advantages of one over the other. METHODS: A systematic search of PubMed, EMBASE, and Cochrane databases identified studies comparing HPSD to LPLD ablation. All the analyses used the random-effects model. RESULTS: Ablation settings varied widely across 20 studies comprising 2,136 patients who underwent HPSD and 1,753 patients who underwent LPLD. The pooled incidence of atrial arrhythmia recurrence after HPSD ablation was 20% [95% confidence interval (CI): 0.16-0.25; I2=88%]. Atrial arrhythmia recurrences were significantly less frequent with HPSD ablation (incidence risk ratio=0.66; 95% CI: 0.49-0.88; I2=72%; p=0.004). Procedural, fluoroscopy, and ablation times were significantly shorter with HPSD ablation. First-pass pulmonary vein isolations (PVIs) were significantly more [odds ratio (OR)=2.94; 95% CI: 1.50-5.77; I2=89%; p=0.002), and acute pulmonary vein reconnections (PVRs) were significantly lesser (OR=0.41; 95% CI: 0.28-0.62; I2=62%; p<0.001) in the HPSD group. Although radiofrequency energy was significantly higher, esophageal thermal injuries (ETI) were lower with HPSD ablation. Acute complications, including steam-pops, were rare and statistically similar in both the groups. CONCLUSION: HPSD ablation enables faster first-pass PVI with fewer PVRs, similar ETI rates, rare collateral damage, and lower recurrence of atrial arrhythmia in the long term than LPLD. Randomized controlled studies with a larger cohort are indicated both to confirm the benefit of HPSD ablation and standardize the ablation protocol.
Authors: Shaojie Chen; Boris Schmidt; Alexander Seeger; Stefano Bordignon; Shota Tohoku; Franziska Willems; Lukas Urbanek; Christina Throm; Athanasios Konstantinou; Karin Plank; Max Hilbert; Simone Zanchi; Lorenzo Bianchini; Fabrizio Bologna; Nikolaos Tsianakas; Claudia Kreuzer; K R Julian Chun Journal: Heart Rhythm Date: 2020-05-26 Impact factor: 6.343
Authors: Alex Baher; Mobin Kheirkhahan; Stephen J Rechenmacher; Qussay Marashly; Eugene G Kholmovski; Johannes Siebermair; Madan Acharya; Mossab Aljuaid; Alan K Morris; Gagandeep Kaur; Frederick T Han; Brent D Wilson; Benjamin A Steinberg; Nassir F Marrouche; Mihail G Chelu Journal: JACC Clin Electrophysiol Date: 2018-09-26
Authors: T Jared Bunch; Heidi T May; Tami L Bair; Brian G Crandall; Michael J Cutler; Charles Mallender; J Peter Weiss; Jeffrey S Osborn; John D Day Journal: Heart Rhythm Date: 2019-08-06 Impact factor: 6.343
Authors: Douglas L Packer; Daniel B Mark; Richard A Robb; Kristi H Monahan; Tristram D Bahnson; Jeanne E Poole; Peter A Noseworthy; Yves D Rosenberg; Neal Jeffries; L Brent Mitchell; Greg C Flaker; Evgeny Pokushalov; Alexander Romanov; T Jared Bunch; Georg Noelker; Andrey Ardashev; Amiran Revishvili; David J Wilber; Riccardo Cappato; Karl-Heinz Kuck; Gerhard Hindricks; D Wyn Davies; Peter R Kowey; Gerald V Naccarelli; James A Reiffel; Jonathan P Piccini; Adam P Silverstein; Hussein R Al-Khalidi; Kerry L Lee Journal: JAMA Date: 2019-04-02 Impact factor: 56.272
Authors: Jonathan Ac Sterne; Miguel A Hernán; Barnaby C Reeves; Jelena Savović; Nancy D Berkman; Meera Viswanathan; David Henry; Douglas G Altman; Mohammed T Ansari; Isabelle Boutron; James R Carpenter; An-Wen Chan; Rachel Churchill; Jonathan J Deeks; Asbjørn Hróbjartsson; Jamie Kirkham; Peter Jüni; Yoon K Loke; Theresa D Pigott; Craig R Ramsay; Deborah Regidor; Hannah R Rothstein; Lakhbir Sandhu; Pasqualina L Santaguida; Holger J Schünemann; Beverly Shea; Ian Shrier; Peter Tugwell; Lucy Turner; Jeffrey C Valentine; Hugh Waddington; Elizabeth Waters; George A Wells; Penny F Whiting; Julian Pt Higgins Journal: BMJ Date: 2016-10-12